Accelerate your research with GA-map®

GA-map® can facilitate your research with end-to-end microbiota profiling services that translate complex data into meaningful results. Our workflow features comprehensive gut microbiota profiling as well as standardized, clinically validated parameters for microbiota assessment in clinical research. Send us your study samples to uncover valuable bacteria signatures.

Why GA-map®?

Reference values

50+ publications

70+ clinical trials

Bioinformatic services

Essential microbiota analysis

The GA-map® technology offers a standardized platform that features an end-to-end workflow for targeted microbiota analysis. We provide services tailored for all types of clinical research.

GA-map® Dysbiosis Test is a microbiota test for detection and characterization of dysbiosis in human fecal samples. The test is the first CE-IVD approved assay providing microbiota profiling with an intrinsic healthy reference.

GA-map® Discovery is a Research Use Only, comprehensive, end-to-end microbiota profiling service for clinical and industry research. The service provides deep insight into gut and oral microbiota, based on analysis of over 170 clinically important bacteria.

Learn more about GA-map® Discovery here.

GA-map® Dysbiosis Test features

Dysbiosis index

Reference population


Bacterial abundance

GA-map® Discovery features

Comprehensive gut panel

Oral bacteria markers

In-depth profiling

Opportunistic pathogens

Services we offer

Service Lab

We offer time- and cost-effective microbiota analyses. Choose between the CE-IVD GA-map® Dysbiosis Test and the RUO GA-map® Discovery. Our service lab is fully equipped and ready to analyze your samples!

Scientific advice

Our team has an extensive expertise in clinical research in the gut microbiota field. Our clinical research experts are ready to help you develop and finalize your study protocol. We also offer clinical study design.


Our experienced bioinformatics team can perform data analysis tailored to supply you with ready-to-publish statistics and results in various visualizations.

R&D consultancy

Are you looking to put together a pre-selected bacterial panel or have you identified a specific signature? The GA-map® technology provides the perfect platform for transforming your results into ready-to-use diagnostic solutions. Develop your test with GA-map®.

Curious to learn more about our newest Research Use Only microbiota profiling service? Read more about GA-map® Discovery here.

Do our services fit your needs? Reach out for a non-binding conversation.

Contact us

Benefits of the GA-map® technology

Speed and throughput

Results in 1-2 days for a 96-well plate

Cost efficiency

Low cost per sample


Species level resolution


Standardized, highly accurate and reproducible results

Pre-determined approach

A panel targeting only the relevant bacteria


Detects multiple bacteria targets simultaneously

16s rRNA Sequencing
Shotgun metagenomics

GA-map® Dysbiosis Test

Reference values

Relative abundance compared to healthy normal

No data processing steps

Patented algorithm providing ready-to-use results

Dysbiosis Index

Validated gut microbiota dysbiosis indicator

CE-IVD approved

Meets high safety, health, and environmental requirements


The GA-map® technology holds the potential for development of In-Vitro Diagnostic (IVD) tests for all diseases and conditions where the microbiota is involved.

An increasing number of researchers have discovered the efficiency and simplicity of the GA-map® Dysbiosis Test in gut microbiota analysis.

Merging the rapidness, preciseness, and robustness of RT-PCR approaches with the comprehensiveness of next-generation sequencing, the GA-map® technology drastically reduces the time from analysis to publication.

The GA-map® technology has until now been applied in clinical research in the fields of gastroenterology (IBS and IBD) and metabolic disorders (Diabetes and Obesity).

We used GA-map® in our clinical research within IBS. We have great experience with GA-map® as a tool to select, monitor and follow-up patients.

Professor Magdy El-Salhy

Stord Hospital, Helse Bergen and the University of Bergen, Norway

Professor Magdy El-Salhy

There is still so much to learn about the microbiome, we are only just beginning to discover its importance, and the GA-map® Dysbiosis Test will help us do just that.

Emeritus Professor Peter Malfertheiner

Senior Professor at the Ludwig Maximillian University, University Clinic in Munich, Germany

Emeritus Professor Peter Malfertheiner

What is GA-map® technology?

The unique GA-map® technology presents a different approach in microbiota analysis from other methods currently in use in research and clinical diagnostics. GA-map® is a pre-selected target multiplex platform allowing simultaneous analysis of a large number of bacteria in a single reaction. Our technology utilizes sequence variations between different bacteria groups or species for detection and quantification.

GA-map® uses almost the full length of the 16S gene (variable regions V3-V9) to detect bacteria at low taxonomic levels (genus and species). Bacteria marker panels built on the GA-map® platform can simultaneously target multiple bacteria on different taxonomic levels.

Depending on the composition of bacteria present in each sample, the probes in the GA-map® panel will bind to their respective target DNA and produce a signal.

The assay incorporates MagPlex® microspheres for solid phase hybridization and easy readout on Luminex®200™ or MAGPIX® instruments (Luminex Corp.). The workflow allows a short turnaround time of 1-2 days.

Find out more about the Luminex® instruments here:

Visit the Luminex website for information on the instruments

Industry partners

Academic Network

Frequently asked questions

The gut microbiota is the most abundant microbiota in the human body. We have a set of core functional bacteria that are involved in vital functions such as gut-barrier defense, nutrition and behavior. These core functional bacteria are common to all healthy humans. However, each individual's gut microbiota composition is mostly unique.

Gut bacteria composition can be influenced by various factors such as parental microbiota, genetics, age, diet, environment and medication.

Under normal conditions, the various bacteria species present in the human gut exist in a balance. A loss of this balance, resulting in alterations to the gut microbiota composition (loss of species diversity or overgrowth of single bacteria species) is called dysbiosis.

Gut microbiota dysbiosis is often associated with overgrowth of opportunistic pathogens and depletion of commensal bacteria, resulting in disturbances of the microbiota’s digestive and anti-inflammatory functions. Dysbiosis can be induced by various external factors, some of which are: low-fiber diet, antibiotic intake or excessive alcohol consumption. Dysbiosis is also associated with a number of diseases.

Gut microbiota dysbiosis is often associated with overgrowth of opportunistic pathogens and depletion of commensal bacteria, resulting in disturbances of the microbiota’s digestive and anti-inflammatory functions. Functional impairments can lead to inflammation of the intestinal mucosa, which in turn can take part in the development of chronic diseases.

Accumulating evidence show a profound association between dysbiosis and a wide range of health disorders, including irritable bowel syndrome, inflammatory bowel diseases, colorectal cancer, non-alcoholic fatty liver disease, major depression disorder, autism spectrum disorder, Parkinson’s disease, obesity, and many others.

The GA-map® technology utilizes instruments commonly used in clinical laboratories. Follow our Pre Installation Guide to check if your lab is equipped with the right instruments.

Our technology transfer team will assist you throughout the installation process and perform comprehensive training for your staff.

We will make sure you have everything you need to start running the GA- map® assay. Close follow-ups are always included in our technology transfer service.

Contact us for more information about technology transfer.

GA-map® utilizes well-established molecular lab techniques and instruments commonly used in clinical laboratories. DNA extracted from the samples does not require extensive processing or library preparation, allowing for complete analysis from sample to result in 1-2 days.

As part of our CE-IVD GA-map® Dysbiosis Test, the GA-map® software performs quality control and generates sample reports with no need for additional data processing steps. The GA-map® Dysbiosis Test is complemented with an instruction video and a detailed user manual.

GA-map® Dysbiosis Test assay uses a selection of 48 probes targeting >300 bacteria on different taxonomic levels. Samples from a normobiotic reference population were used to develop a dysbiosis model with a bacterial profile and Dysbiosis Index score output.

The model algorithmically assesses fecal bacterial abundance and profiles, and potential clinically relevant deviation in the microbiome from normobiosis. This model was tested and validated on samples from healthy volunteers, IBS and IBD patients to determine the ability to detect dysbiosis.

GA-map® Dysbiosis Test is well documented and standardized for clinical routine testing and provideshighly repeatable, easy to interpret results.

The GA-map® Dysbiosis Test is designed to diagnose and characterize dysbiosis from a fecal sample. The test has been validated using independent cohorts of healthy volunteers, IBS and IBD patients.

The test was developed using the GA-map® technology, utilizing amplification of the 16S rRNA gene, present in all bacteria, for simultaneous detection of 48 clinically relevant bacteria markers.

GA-map® Discovery is a Research Use Only bacteria profiling service based on the GA-map® platform. The panel includes over 170 bacterial markers covering both gut and oral microbiota, with each marker representing microorganisms of high clinical significance in gastrointestinal and metabolic disease. Find out more about GA-map® Discovery here.

Interested in including GA-map® Discovery analysis in your research? Contact us for details.

The GA-map® platform utilizes a pre-determined target approach, where each bacterial marker has documented specificity, making the results independent of external database hits. Tests developed on our platform have proven high reproducibility.

Under development of GA-map® Dysbiosis Test, cohorts of both healthy individuals as well as IBS and IBD patients were used to establish a healthy reference population with relative abundance of bacteria species, and to assess deviations from the normobiotic composition. GA-map® Dysbiosis Test is CE marked and IVD-R compliant. Standardization of the test ensures repeatable and accurate results. GA-map® reagent kits are produced following the ISO 13485 standard for medical devices.

The GA-map® Dysbiosis Test reagent kit contains all the reagents required for the analysis. Additional kits are required for gDNA isolation and quantification.

GA-map Discovery® is run for you entirely in our Service lab. All you need to do is send us your samples, we will send you the results. No pre-analysis preparation needed.

The unique, patented algorithm in the GA-map® software calculates the Dysbiosis Index, several functional bacteria profiles and relative abundance of 48 clinically relevant bacteria for each sample.

The results are presented in an easy-to-read report form generated by the GA-map® software. Alternatively, the results can be exported via a LIMS software and used to generate customized report forms.

See an example of the report form here: Report form pdf

Get started with GA-map®

Curious to learn more?